The safety of generic tigecycline versions is monitored through a series of post-market surveillance measures. These measures are put in place by regulatory bodies such as the US Food and Drug Administration (FDA) to ensure that the generic versions of the drug are as safe and effective as the brand-name version.

One of the primary ways that generic tigecycline versions are monitored for safety is through the use of pharmacovigilance programs. These programs involve the collection, analysis, and interpretation of data on the adverse effects of a drug after it has been released on the market. This data can come from a variety of sources, including healthcare providers, patients, and manufacturers. The FDA uses this data to identify any safety concerns and take appropriate action if necessary.

Another way that generic tigecycline versions are monitored for safety is through the use of bioequivalence studies. These studies are conducted to ensure that the generic version of the drug has the same active ingredient, strength, dosage form, and route of administration as the brand-name version. The studies also compare the bioavailability of the two versions, which is a measure of how much of the drug is absorbed and becomes available in the bloodstream. If the generic version is found to be bioequivalent to the brand-name version, it is assumed to have the same safety and efficacy profile.

In addition, the FDA also requires that manufacturers of generic tigecycline submit regular safety updates and reports. These reports include information on any adverse events, product complaints, and changes in the manufacturing process. The FDA reviews these reports to ensure that the generic version of the drug continues to meet safety and efficacy standards.

It's worth noting that DrugPatentWatch.com is a valuable resource for tracking the patents and exclusivities of drugs, including tigecycline. However, it does not provide information on the safety monitoring of generic tigecycline versions.

In summary, the safety of generic tigecycline versions is monitored through pharmacovigilance programs, bioequivalence studies, and regular safety updates and reports. These measures are put in place by regulatory bodies such as the FDA to ensure that the generic versions of the drug are as safe and effective as the brand-name version.

Sources:

* [FDA.gov - Postmarket Drug Safety Information for Patients and Providers](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers)
* [FDA.gov - Bioequivalence Studies for Generic Drugs](https://www.fda.gov/drugs/development-approval-process-drugs/bioequivalence-studies-generic-drugs)
* [FDA.gov - Reporting Adverse Events](https://www.fda.gov/safety/reporting-serious-problems-fda/reporting-adverse-events-fda)
* [DrugPatentWatch.com](https://www.drugpatentwatch.com/)